Close X
Attorney Spotlight

What colorful method does Claire Miley use to keep up with the latest healthcare regulations as they relate to proposed transactions? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Pennsylvania's New Non-Resident Pharmacy Licensure Requirement

Publications

October 8, 2015

Soon, Pennsylvania will become the 50th state to require non-resident pharmacy licensure. On October 7, 2015, Pennsylvania Governor Tom Wolf approved House Bill 75, which requires non-resident pharmacies to register with the Pennsylvania Board of Pharmacy (the "Board") before delivering prescriptions to Pennsylvania patients. Although the law takes effect on December 6, 2015, the Board may delay enforcement of the requirement until the Board can create and finalize a non-resident pharmacy licensure process.

Pennsylvania licensure will impose additional compliance requirements for non-resident pharmacies. For example, a licensed non-resident pharmacy must:

  • Maintain a toll-free telephone number through which the patient can access a pharmacist and operational during the pharmacy's regular hours of operation, but not less than six days per week for a minimum of 40 hours per week;
  • Affix this toll-free telephone number to the prescription label;
  • Notify the Board within 30 days of final disposition of any disciplinary action taken by the licensing agency in the non-resident pharmacy's home state; and
  • Notify the Board within 30 days of a change in location or pharmacist-in-charge.

House Bill 75 also creates new requirements for Pennsylvania pharmacies. Pennsylvania pharmacies licensed in other states must now disclose such licensure pursuant to the Pennsylvania license renewal process. The Board will note any non-resident license on the pharmacy's record, and any such non-resident state shall be notified by the Board of any disciplinary action taken against the pharmacy in Pennsylvania. Finally, resident pharmacies are required to report to the Board any disciplinary action taken against the pharmacy in another state within 30 days of final disposition.

Once the non-resident licensure requirement takes full effect, every pharmacy located outside Pennsylvania that delivers prescriptions to Pennsylvania patients or advertises in Pennsylvania will be required to obtain a non-resident pharmacy license. If you have questions about Pennsylvania's new non-resident licensure requirement, please contact the authors of this alert or any member of our Specialty Pharmacy team.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.